NDAINJECTIONINJECTABLEPriority Review
Approved
May 1970
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 13h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Mithracin (plicamycin) is a small-molecule antibiotic chemotherapy agent approved in 1970 for treating testicular cancer and hypercalcemia of malignancy. It functions as a DNA intercalating agent that inhibits RNA synthesis in cancer cells and osteoclasts. The drug is administered intravenously and represents an older, established oncology treatment.
LOE Approaching
Product is in late-stage lifecycle with limited growth opportunity; commercial team likely focused on maintenance and transition planning rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on Mithracin offers limited career advancement given the product's late-lifecycle status and minimal job openings. Roles available are primarily in compliance, supply-chain management, and regulatory maintenance rather than commercial growth or innovation.
Supply Chain ManagerRegulatory Affairs Specialist
Worked on MITHRACIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.